Better Health for All

Longeveron's entire business is devoted to developing cellular therapies for life-threatening and chronic aging-related conditions, including Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s Disease, and Aging Frailty.

Their lead product, Lomecel-B, is an investigational therapeutic. Phase 1 trials for HLHS showed 100% transplant-free survival up to 5 years, and Phase 2a Alzheimer's trials showed positive results in slowing disease progression. The company has no revenue from products with negative health impacts. In the CLEAR MIND Phase 2a trial (50 patients), one Serious Adverse Event (SAE) was reported on each Lomecel-B treatment group, with no safety issues raised by the Data and Safety Monitoring Board (DSMB). The company sponsors a Treatment Registry Trial in The Bahamas where participants receive Lomecel-B at their own expense, which is an investigational therapeutic not approved in the US or The Bahamas. This trial's revenue decreased by 30% in Q1 2025 due to decreased participant demand. Longeveron is developing therapies for conditions affecting vulnerable populations like infants (HLHS) and older adults (Alzheimer's, Aging Frailty). The company includes forward-looking statements acknowledging potential risks and uncertainties. Longeveron is a clinical-stage regenerative medicine biotechnology company, with R&D expenses of $8.1 million in 2024 and $2.5 million in Q1 2025. They collaborate with the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute on Aging, and received a Part the Cloud grant from the Alzheimer’s Association. Longeveron supports the Rare Pediatric Disease Priority Review Voucher Program. Lomecel-B is being tested to improve vaccine response in patients with Aging Frailty and for Acute Respiratory Distress Syndrome (ARDS). The Treatment Registry Trial in The Bahamas operates under the approval of the National Stem Cell Ethics Committee (NSCEC).

Fair Pay & Worker Respect

The provided articles focus on Longeveron Inc.'s clinical trial progress, financial results, FDA designations, and board changes.

No information regarding employee compensation, workplace safety, labor practices, or worker engagement was found to assess the company against the 'Fair Pay & Worker Respect' ethical value.

Honest & Fair Business

No specific quantitative data was found in the provided articles to assess Longeveron Inc. against any of the 'Honest & Fair Business' KPIs, including regulatory fines, transparency index scores, whistleblower policy strength, financial restatements, audit coverage, ESG controversy scores, complaint resolution time, board conflict-free percentage, anti-corruption policy strength, or third-party verification of ethical claims.

The documents primarily outline corporate governance structures and committee charters without providing performance metrics.

Kind to Animals

Longeveron Inc. conducts pre-clinical studies of its drugs on animals to assess product safety.

Its Lomecel-B cell-based therapy product has been tested on animals, including for amyloidosis and to assess anti-inflammatory and pro-regenerative properties. Animal studies have also been conducted for Hypoplastic Left Heart Syndrome (HLHS). There is no evidence of a formal policy to limit or reduce animal testing, nor any mention of alternative testing methods. The company's lead product, Lomecel-B, is derived from human bone marrow, indicating zero animal inputs for this product, making the 'ethical_input_sub_pct' KPI not applicable.

No War, No Weapons

Longeveron Inc. is a clinical stage biotechnology company focused on developing cellular therapies for medical conditions.

The company's core business does not involve defense or arms-related activities. There is no evidence of revenue from arms or defense contracts, nor any involvement in dual-use technologies with military applications. The company does not engage in sales to embargoed regimes, peacebuilding investments, or conflict divestment policies. There is no indication of board oversight for defense activities, export compliance requiring end-user certificates, or lobbying related to arms control. Furthermore, the company has no reported defense procurement, human rights due diligence in conflict areas, Arms Trade Treaty declarations, AI systems with military uses, UN Guiding Principles alignment, dual-use item screening, surveillance contracts, or ethical red lines related to weapons. There is no exposure to controversial weapons, war-risk audits, or conflict-linked partners. The company has no defense assets to divest, no mineral inputs requiring conflict-free certification, no peace technology investment ratio, and no procurement from conflict-affected areas. The company's Code of Business Conduct and Ethics prohibits weapons of any kind on company property or in vehicles while on company business, with an exception for specifically authorized security personnel.

Planet-Friendly Business

No specific, concrete data points were found in the provided articles for any of the 'Planet-Friendly Business' KPIs.

The articles primarily focus on the company's clinical trials, strategic plans, financial performance, and regulatory milestones. Several articles explicitly state that sustainability or environmental data is not mentioned or available, or that no data relevant to planet-friendly business practices is provided.

Respect for Cultures & Communities

The provided articles do not contain specific, concrete evidence for any of the Key Performance Indicators related to the ethical value 'Respect for Cultures & Communities'. While one article mentioned 'two private partner clinics in Nassau,'

these are not considered 'indigenous or local community groups' as defined by the rubric for formal partnerships. Consequently, no KPIs can be scored based on the available information.

Safe & Smart Tech

The company provides regular, mandatory training for personnel regarding cybersecurity threats.

It deploys technical safeguards, including access controls, to protect its information systems. The company's vulnerability management involves deploying technical safeguards that are evaluated and improved through vulnerability assessments and penetration testing. It also engages in periodic assessment and testing of cybersecurity measures, including audits, assessments, tabletop exercises, threat modeling, vulnerability, and penetration testing. The company's cybersecurity policies, standards, processes, and practices are based on recognized frameworks established by the National Institute of Standards and Technology, the International Organization for Standardization, and other applicable industry standards.